With this issue we inaugurate a new section—NeuroTherapeutics—which will be edited by Ira Shoulson, Assistant Editor. The scope and objectives of this new section are outlined in an editorial by Dr Shoulson Article, and the first review, "Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial," by FahnArticle, appears in this issue. We invite scholarly and well-focused reviews directed at NeuroTherapeutics. Dr Fahn's review provides a comprehensive, critical assessment of the clinical value and limitations of levodopa therapy in Parkinson disease. His contribution is a masterpiece on this subject and will be an indispensable reference.
This Month in The Archives of Neurology. Arch Neurol. 1999;56(5):515–516. doi:10.1001/archneur.56.5.515
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: